Probability of Target Attainment Analyses to Inform Ceftolozane/Tazobactam Dosing Regimens for Patients With Hospital‐Acquired or Ventilator‐Associated Bacterial Pneumonia and End‐Stage Renal Disease Receiving Intermittent Hemodialysis
Sign Up to like & getrecommendations! Published in 2022 at "Journal of Clinical Pharmacology"
DOI: 10.1002/jcph.2149
Abstract: ASPECT‐NP, a phase 3 trial of ceftolozane/tazobactam in hospital‐acquired/ventilator‐associated bacterial pneumonia (HABP/VABP), excluded patients with end‐stage renal disease (ESRD). A modeling/simulation approach was undertaken to inform optimal dosing in this population, using previously developed ceftolozane… read more here.
Keywords: ceftolozane tazobactam; ceftolozane; acquired ventilator; hospital acquired ... See more keywords